Endurance Bio

Executive Summary

Endurance Bio is a San Francisco-based biotechnology company developing first-in-class small molecule therapeutics that rejuvenate cellular mitochondria and lysosomes. Founded in 2021, the company aims to address a range of diseases, with an initial focus on major neurodegenerative disorders. Its lead candidate, T-168, is poised to enter Phase 2 trials, targeting mitochondrial and lysosomal dysfunction—key hallmarks of neurodegeneration. The company's approach leverages a deep understanding of cellular rejuvenation pathways, potentially offering disease-modifying effects beyond symptomatic relief. While still in early clinical stages, Endurance Bio's platform could have broad applicability across aging-related conditions, including rare genetic disorders. The upcoming Phase 2 trial initiation represents a critical milestone, with data readouts anticipated to provide initial proof-of-concept in patients. The company operates in a competitive landscape but differentiates with a dual-target mechanism. Executing well on clinical development and securing additional funding will be key to advancing its pipeline and validating its therapeutic hypothesis.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 trial initiation for T-168 in major neurodegenerative disorder40% success
• Q1 2027Preclinical data for next-generation candidates or expansion into new indications50% success
• H2 2026Series A or B financing round to support clinical development60% success